Expression and Clinical Significance of Large Tumour Suppressor Kinase 2 (LATS2) Gene in Acute Myeloid Leukaemia: An Egyptian Study XC08-XC12
Dr. Rasha Abd El Razek Khattab,
31 Dr Abd Allah ElArabi-elhay Elsabeh- Nasr City, Cairo, Egypt.
Introduction: Large Tumour Suppressor (LATS) family proteins were discovered for the first time in Drosophila in 1995. Since that date, LATS proteins have been considered tumour suppressors. The family includes two members, LATS1 and LATS2, which have a chief function in the control of tumour growth and cell cycles through several mechanisms and signalling pathways, including those of p53, Hippo, and Wnt. LATS2 gene was involved in many types of haematological malignancies as it plays a role in the leukaemogenesis of AML and also in the clinical outcome of the disease.
Aim: The current study was an attempt to clarify the relation of LATS2 gene expression and clinical manifestations of Acute Myeloid Leukaemia (AML).
Materials and Methods: The present case-control study included 60 adult denovo AML patients and 60 age and sex matched healthy controls for analysis of LATS2 mRNA gene expression level by Real Time-Quantitative Polymerase Chain Reaction (RT-QPCR) technique. Data were analysed using IBM SPSS advanced statistics version 22.0 (SPSS Inc., Chicago, IL).
Results: The expression level of LATS2 gene was significantly higher in AML patients compared to controls (p<0.001). The results showed positive association between LATS2 gene and hepatomegaly and splenomegaly. Mean expression level of LATS2 was higher in patients with hepatomegaly and splenomegaly. The difference was statistically significant (p<0.05). LATS2 gene expression level associates with follow-up of patients as the present study revealed lower LATS2 gene expression (77.45±100.29) in the 40 patients who achieved complete remission (66.7%) than in the 8 patients (13.3%) who achieved partial remission as their mean expression level was (147.18±160.24) compared to higher LATS2 gene expression (239.83±281) in the 12 AML patient (20%) who didnâ€™t achieve CR. The difference was statistically significant (p=0.002).
Conclusion: This study established that LATS2 gene expression was higher in AML patients with extramedullary infiltration. So, LATS2 gene might be a valuable new marker in the diagnosis and prognosis of AML patients.